Figure 2.

CD169 Plays a Protective Role during Pathogenic FVC Infection

(A–C) Kaplan-Meier survival curves of BALB/cJ mice treated with control or CD169-blocking antibodies (n = 4 or 5 per group) as indicated in the schematic (A) after s.c. challenge with 2,500 spleen focus-forming units (SFFU) (B) or 500 SFFU (C) of FVC.

(D) Scheme showing administration regimen for FVC (s.c. 500 SFFU) and isotype control or CD169 blocking antibody via s.c. injections in BALB/cJ mice over a period of 8 days.

(E–H) FVC-infected cells or plasma virus titer for the experiment outlined in (D) in pLNs (n = 8) (E), plasma (n = 5) (F), and spleen (n = 6) (G), as well as the weight of the spleen (n = 6) (H).

(I–M) FVC-infected cells in the pLN (n = 8) (I) and the spleen (n = 5) (J and L), as well as the weight of the spleen (K and M) at indicated days after s.c. inoculation with 2,500 SFFU of FVC in B6, CD169^−/−, B6.Fv2^s/s, and B6.Fv2^s/s CD169^−/− mice.

(N) Scheme depicting possible path of blood-borne retrovirus via the heart to spleen, the main blood-filtering lymphoid tissue, and its subsequent spread to secondary draining sites such as pLN following r.o. inoculation.

(O–Q) FVC-infected cells in the spleen (n = 5) (O) and pLN (n = 10) (Q), as well as spleen weight (P), are shown for B6 and CD169^−/− mice 8 days after r.o. administration with 2,500 SFFU of FVC.

p values derived from non-parametric Mann-Whitney test; mean values denoted by horizontal line. See also Figure S1.